[go: up one dir, main page]

AR132848A1 - Agonistas espiromacrocíclicos de receptores de orexina 2 - Google Patents

Agonistas espiromacrocíclicos de receptores de orexina 2

Info

Publication number
AR132848A1
AR132848A1 ARP240101407A ARP240101407A AR132848A1 AR 132848 A1 AR132848 A1 AR 132848A1 AR P240101407 A ARP240101407 A AR P240101407A AR P240101407 A ARP240101407 A AR P240101407A AR 132848 A1 AR132848 A1 AR 132848A1
Authority
AR
Argentina
Prior art keywords
spiromacrocyclic
orexin
receptor agonists
novel
compounds
Prior art date
Application number
ARP240101407A
Other languages
English (en)
Inventor
Karsten Juhl
Wanwan Yu
Leegaard Thomas Andersen
Erhad Ascic
Michael Bk
Gitte Kobbere Mikkelsen
Andreas Michael Arnold
Anders Hjgaard Hansen
Petra Lindovsk
Henrik Juhani Kernen
Ferran Planas Padrs
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of AR132848A1 publication Critical patent/AR132848A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a compuestos espiromacrocíclicos novedosos de fórmula general (1) que son agonistas de receptores de orexina 2.
ARP240101407A 2023-06-01 2024-05-31 Agonistas espiromacrocíclicos de receptores de orexina 2 AR132848A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP23176747 2023-06-01
EP24174838 2024-05-08

Publications (1)

Publication Number Publication Date
AR132848A1 true AR132848A1 (es) 2025-08-06

Family

ID=91431272

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP240101407A AR132848A1 (es) 2023-06-01 2024-05-31 Agonistas espiromacrocíclicos de receptores de orexina 2

Country Status (9)

Country Link
US (2) US20240425521A1 (es)
CN (1) CN121219296A (es)
AR (1) AR132848A1 (es)
AU (1) AU2024278752A1 (es)
CO (1) CO2025017638A2 (es)
IL (1) IL324946A (es)
MX (1) MX2025013714A (es)
TW (1) TW202448426A (es)
WO (1) WO2024246285A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025211415A1 (ja) * 2024-04-04 2025-10-09 キッセイ薬品工業株式会社 置換スルホンアミド化合物
WO2025211416A1 (ja) * 2024-04-04 2025-10-09 キッセイ薬品工業株式会社 置換スルホンアミド大環状化合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20190475A1 (es) 2016-08-15 2019-04-04 Pfizer Inhibidores de cdk2/4/6
US11542276B2 (en) 2019-11-25 2023-01-03 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment
CN116635393A (zh) 2020-09-03 2023-08-22 欧瑞夏治疗有限公司 中环或大环苄基取代的杂环衍生物及其作为食欲素-2受体激动剂的用途
WO2022094012A1 (en) 2020-11-02 2022-05-05 Merck Sharp & Dohme Corp. Macrocyclic urea orexin receptor agonists
EP4247801A4 (en) 2020-11-23 2024-10-30 Merck Sharp & Dohme LLC 3-AMINO PYRROLIDINE AND MACROCYCLIC PIPERIDINE OREXIN RECEPTOR AGONISTS
AU2022267220A1 (en) 2021-04-26 2023-10-19 Alkermes, Inc. Substituted amide macrocyclic compounds with orexin-2 receptor agonist activity
EP4347046A1 (en) 2021-05-26 2024-04-10 Alkermes, Inc. Substituted fused bicyclic macrocyclic compounds and related methods of treatment
KR20250073642A (ko) 2022-10-07 2025-05-27 깃세이 야쿠힌 고교 가부시키가이샤 시클로펜탄 화합물

Also Published As

Publication number Publication date
WO2024246285A1 (en) 2024-12-05
CN121219296A (zh) 2025-12-26
MX2025013714A (es) 2026-01-07
AU2024278752A1 (en) 2026-01-22
CO2025017638A2 (es) 2026-01-13
IL324946A (en) 2026-01-01
US20240425521A1 (en) 2024-12-26
TW202448426A (zh) 2024-12-16
US20250263422A1 (en) 2025-08-21

Similar Documents

Publication Publication Date Title
AR132848A1 (es) Agonistas espiromacrocíclicos de receptores de orexina 2
BR112022009390A2 (pt) Síntese melhorada de composto inibidor de kras g12c
CL2025002125A1 (es) Compuestos novedosos
PE20210548A1 (es) Derivado de amino-fluoropiperidina como inhibidor de quinasa
PH12013501196B1 (en) Indeno- fused ring compounds having photochromic properties
FR3087439B1 (fr) Procédé pour la préparation de 3α-hydroxy-5α-prégnan-20-one (brexanolone)
CO2023004195A2 (es) Compuestos heterocíclicos
CO2023010212A2 (es) Derivados novedosos de pirimidin-2-il sulfonamida
UY38941A (es) Nuevas sulfiliminas o sulfoximinas que contienen compuestos heterocíclicos fungicidas
BR112023017834A2 (pt) Inibidores de lrrk2 cinase macrocíclicos
WO2023199091A8 (en) Heterocyclic compound
CL2024003023A1 (es) Inhibidores lrrk2.
CY1118170T1 (el) Νεα φωσφινικα οξεα και παραγωγα θειου αυτων και μεθοδοι για την παρασκευη τους
CO2021000940A2 (es) Procedimiento y productos intermedios para la preparación de bilastina
BR112021026899A2 (pt) Compostos heterocíclicos
CL2025000283A1 (es) Composición biocida
MX2021008654A (es) Complejo de gadolinio y un ligando quelatante derivado de pcta diastereoisomericamente enriquecido y metodo de sintesis.
AR126648A1 (es) Métodos para hacer un modulador de hemoglobina
UY38943A (es) Nuevas heteroaril piperidiniletanonas sustituidas de 6 miembros
FR3097223B1 (fr) Adduits silylés, polymères silylés et compositions les comprenant
BR112021026061A2 (pt) Método para o tratamento de uma composição que compreende vanilina natural
MX2021014111A (es) Proceso para la preparacion de epimeros de fosforamidita de galnac.
AR130483A1 (es) Inhibidores de la cinasa con repeticiones ricas en leucina 2 (lrrk2)
MX2023015490A (es) Inhibidores de las transglutaminasas.
BR112023003328A2 (pt) Preparação de composto acrilato substituído